Shanghai Henlius Biotech : VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE LICENSE AGREEMENT WITH NEUPHARMA IN RESPECT OF SMALL-MOLECULE INHIBITOR RX208 TARGETING V600E MUTATION IN HUMAN BRAF PROTEIN
May 12, 2021 at 06:52 am
Share
the small-moleculeinhibitor RX208 targeting V600E mutation in human BRAF protein (the "Licensed Product") (product code of the Company: HLX208)
1
Licensed Product
NeuPharma (as the licensor)
the Company (as the licensee); and
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2696)
VOLUNTARY ANNOUNCEMENT
ENTERING INTO THE LICENSE AGREEMENT WITH
NEUPHARMA IN RESPECT OF
SMALL-MOLECULE INHIBITOR RX208 TARGETING V600E
MUTATION IN HUMAN BRAF PROTEIN
INTRODUCTION
Reference is made to the announcement of Shanghai Henlius Biotech, Inc. (the "Company") dated 28 March 2021 in relation to the entering into of a binding term sheet with Suzhou NeuPharma Co., Ltd.* ("NeuPharma") in respect of a small-molecule inhibitor RX208 targeting V600E mutation in human BRAF protein.
The board of directors of the Company is pleased to announce that on 11 May 2021, the Company and NeuPharma entered into a drug technology license agreement (the "License Agreement").
PRINCIPAL TERMS OF THE LICENSE AGREEMENT Parties
Cooperation
NeuPharma will grant the Company a sublicensable exclusive license
and License
for related licensed patents and licensed know-how necessary or
reasonably useful for the Company to research, develop, produce and
commercialize the Licensed Product within the Licensed Territory.
At the same time, the Company shall have the right to use the Licensed
Product for any human indications and any types of therapies (including
but not limited to monotherapy, combination therapy or cocktail
therapy).
Licensed Territory
China (including Hong Kong, Macau and Taiwan regions) (the
"Licensed Territory")
Payments and
The Company shall pay NeuPharma:
Royalties
•
upfront payment of an aggregate of RMB97.5 million depending
on the progress of the entering into of the License Agreement, the
issue of invoices by NeuPharma and the transfer of the technical
documents and materials in respect of the Licensed Products;
•
regulatory and commercial sales milestone payments of no
more than RMB1.0775 billion in aggregate based on various
development and commercial sales milestones of the Licensed
Product; and
•
the royalties of 8% to 12% of the annual net sales, which depends
on the level of annual net sales of the Licensed Product in the
Licensed Territory, except for the adjustments and/or deductions
made in accordance with the terms of the License Agreement.
Depending on the effective date of any sublicense, the Company may
need to share the profit from the sublicense with NeuPharma.
Term
Effective from 11 May 2021, until the expiry date of the royalty period
determined in accordance with the License Agreement for all regions in
the Licensed Territory, except for early termination as agreed between
the Company and NeuPharma or as made otherwise in accordance with
the License Agreement.
2
INFORMATION ABOUT THE LICENSED PRODUCT
The Licensed Product is a small-molecule inhibitor targeting the human BRAF protein V600E mutation, which has exhibited excellent drug efficacy and safety in pre-clinical research and is currently in the stage of phase I clinical development. BRAF protein is an important upstream regulator of MAPK/ERK signaling pathway, and its V600E mutation can induce constitutive activity of BRAF protein. It is a potential drug target for a variety of tumors including colorectal cancer, thyroid cancer, melanoma and certain rare diseases including Erdheim-Chester disease (ECD).
On behalf of the Board
Shanghai Henlius Biotech, Inc.
Qiyu CHEN
Chairman
Hong Kong, 11 May 2021
As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the executive director, Mr. Qiyu Chen as the chairman and non-executive director, Mr. Yifang Wu, Ms. Xiaohui Guan, Dr. Aimin Hui and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.
For identification purpose only
3
Attachments
Original document
Permalink
Disclaimer
Shanghai Henlius Biotech Inc. published this content on 11 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 May 2021 10:51:04 UTC.
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Companyâs main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Shanghai Henlius Biotech : VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE LICENSE AGREEMENT WITH NEUPHARMA IN RESPECT OF SMALL-MOLECULE INHIBITOR RX208 TARGETING V600E MUTATION IN HUMAN BRAF PROTEIN